Teprotumumab-associated hearing-related adverse events

  • Amanda Key Texas Tech University Health Sciences Center
  • Addie Pederson
  • Jared Sant
  • Coby Ray


This study aims to provide a review of the existing literature on teprotumumab (Tepezza)-associated hearing-related adverse effects. A review of PubMed and Embase was conducted using keywords “teprotumumab,” “tepezza,” “hearing disorder[s],” “hearing loss,” and “ototoxicity.” These search results were filtered to include all clinical trials, observational studies, case reports, and case series relevant to the topic of teprotumumab-associated hearing disorders. Data collection from the 15 included studies consisted of: sample size, number and percentage of hearing disorders reported, types of hearing disorders, remission rates, timeline of symptom onset, predisposing risk factors, suggested screening guidelines, and treatment proposals. Teprotumumab-associated hearing disorders are reported in 7-81.5% (median 12%) of clinical study participants. Symptoms described include sensorineural hearing loss (SNHL), hypoacusis, autophony, ear fullness/pressure/plugging, patulous eustachian tube, and tinnitus. Most symptoms improve with discontinuation of teprotumumab, but some symptoms persist after completion of treatment, most commonly SNHL. Symptoms have been reported occurring 3-37 (median 8.4) weeks after treatment initiation, with the majority reported 6 weeks after treatment initiation. Additional prospective studies are needed to clarify how frequently teprotumumab causes ototoxicity. There remains a need for both standardized audiologic screening guidelines and treatment for patients in whom ototoxicity persists post-treatment.


Key Words: teprotumumab, tepezza, hearing disorder[s], hearing loss, ototoxicity


Download data is not yet available.
How to Cite
Key, A., Pederson, A., Sant, J., & Ray, C. (2024). Teprotumumab-associated hearing-related adverse events. The Southwest Respiratory and Critical Care Chronicles, 12(50), 24-29. https://doi.org/10.12746/swrccc.v12i50.1261